Toxic cardiomyopathy leading to fatal acute cardiac failure related to vandetanib: a case report with histopathological analysis

Third universal definition of myocardial infarction

(2012) Kristian Thygesen et al.   EUROPEAN HEART JOURNAL

Late Cardiac Effects of Cancer Treatment

(2012) Daniel J. Lenihan et al.   JOURNAL OF CLINICAL ONCOLOGY

Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial

(2011) Samuel A. Wells et al.   JOURNAL OF CLINICAL ONCOLOGY

Medullary Thyroid Carcinoma

(2010) F. Pacini et al.   CLINICAL ONCOLOGY

Cardiovascular Effects in Rats following Exposure to a Receptor Tyrosine Kinase Inhibitor

(2010) Shirley A. Aguirre et al.   TOXICOLOGIC PATHOLOGY

The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro

(2010) Brian B. Hasinoff et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

VEGF receptor switching in heart development and disease

(2009) R. Madonna et al.   CARDIOVASCULAR RESEARCH

Sunitinib-Induced Cardiotoxicity Is Mediated by Off-Target Inhibition of AMP-Activated Protein Kinase

(2009) Risto Kerkela et al.   CTS-Clinical and Translational Science

Heart failure associated with sunitinib malate

(2008) Aarif Y. Khakoo et al.   CANCER

Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma

(2008) Manuela Schmidinger et al.   JOURNAL OF CLINICAL ONCOLOGY